- Research article
- Open Access
- Open Peer Review
This article has Open Peer Review reports available.
Obesity is an independent risk factor for pre-transplant portal vein thrombosis in liver recipients
© Ayala et al.; licensee BioMed Central Ltd. 2012
Received: 6 November 2011
Accepted: 26 July 2012
Published: 21 August 2012
Portal vein thrombosis is a frequent complication in end-stage cirrhosis with a considerable peri-operative risk for liver transplant candidates. We aimed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant recipients, and to identify independent risk factors for this complication.
380 consecutive primary orthotopic liver transplants were performed in the Digestive Surgery Department of “12 de Octubre” Hospital (Madrid, Spain), between January 2001 and December 2006. The main risk factors considered were smoking, obesity, metabolic disorders, previous immobility, surgery or trauma, nephrotic syndrome, associated tumor, inflammatory disease, neoplasm myeloprolipherative. Furthermore we have reported genetic thrombophilia results for 271 recipients.
Sixty-two (16.3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in the overall survival of liver recipients. Obesity was the only independent risk factor for pre-transplant portal vein thrombosis.
We recommend close control of cardiovascular factors in patients with liver cirrhosis in order to avoid associated thrombosis.
Portal vein thrombosis (PVT) is a well recognized complication in patients with end-stage cirrhosis, and its incidence ranges from 2 to 26% in different series . PVT has various causes. The cause may be local, such as cirrhosis, primary or metastatic liver cancer, pylephlebitis, vascular abnormalities, and pancreatitis. Alternatively PVT may result from a thrombophilic condition such as myeloproliferative disease, Protein C (PC), Protein S (PS) and Antithrombin (AT) deficiency, or Factor V Leiden and Factor IIG20210A carriers, or a combination of a primary thrombophilia milieu that triggers the formation of the thrombus in the portal circulation .
PVT continues to be associated with a considerable peri-operative risk for liver transplant candidates [3, 4], and is associated with increased operative time, transfusion requirements, re-interventions, and lower survival rate relative to PVT extension . Therefore, PVT has been seen as an obstacle to orthotopic liver transplantation (OLT).
We aimed to identify possible parameters that could lead to PVT in a cohort of liver transplant recipients. The influence of this thrombosis in the survival of liver recipient was also evaluated.
This work is related to our previous publication  where we analyzed the post-transplant thrombotic events in a cohort of liver transplant recipients to identify possible parameters that could lead to HAT and could be responsible for graft loss due to thrombosis in a extended thrombophilia study. Our results showed that high fibrinogen and decreased protein C levels were parameters associated with allograft thrombosis. In the present study we analyzed the factors related to portal vein thrombosis in the pre-transplant period and their prognostic implications.
Materials and methods
Between January 2001 and December 2006, 380 primary orthotopic liver transplants (OLT) were performed in the Digestive Surgery Department of the 12 de Octubre Hospital (Madrid, Spain). Wherever possible all patients are lab tested for genetic hypercoagulation study irrespective of any presence of thrombophilia. We have reported genetic thrombophilia and JAK2 mutations results for 271 primary OLT recipients. The study was approved by our Institutional Review Board and all patients gave their consent for blood samples to be further processed. Data on thrombophilia risk factors were collected by personal interview, or by reviewing the medical history.
The study population comprised 254 males and 126 females. The cause of liver transplantation was: 18 HBV (hepatitis B virus), 73 HCV (hepatitis C virus), 52 HBV and HCV, 62 Ethanol, 8 Autoimmune, 8 Toxicity, 29 Tumor, 63 HBV or HCV and tumor, 2 Vascular, 26 Alpha 1 antitrypsin deficits, 24 Biliary atresia and 15 cryptogenetic.
Genetic thrombophilia study
The extracted genomic DNA was processed to detect Factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate (MTHFR) C667T mutations, using real-time PCR (polymerase chain reaction) with hybridization probes in a light-cycler (Roche Diagnostics, Mannheim, Germany).
JAK2 mutations study
JAK2 V617F ASO quantitative PCR (ASO qPCR) was performed with the ABI PRISM 7900 (Applied Biosystems, Palo Alto, CA, USA), and a forward ASO primer spanning of the JAK2 V617F mutation region. A reverse primer and MGB TaqMan probe were also employed .
The follow-up period for recipients began on the date of liver transplantation, and ended on the date of death, date of re-transplant, or the end of study (March 1, 2007). Follow-up periods ranged from 15 d to 6.9 y (median: 20.23 months).
The Pearson’s chi-square (χ2) statistic and the Student’s t test were used to test for differences in the distribution of dichotomous variables, and for differences in the mean values of continuous distributions. Forward stepwise logistic regression was used to identify independent risk factors for PVT. The following variables collected at diagnosis were included in the database: gender (male/female), age (both as a continuous variable, and grouping patients over and under 16 years of age), the existence of clinical thrombophilia risk factors and the original liver disease.
Overall survival (OS) was calculated from the day of the liver transplantation to death. Kaplan-Meier life tables were constructed for survival data and were compared by means of the log-rank test. A census of the surviving patients was taken on March 1, 2007. Results with a P value less than 0.05 were considered significant.
Thrombophilia in the study population
Genetic study in association with pre-transplant PVT in liver recipients
With Pre-transplant PVT (50 cases)
Without Pre-transplant PVT(221 cases)
Factor V Leiden mutation (Nº) (heterozygous) in recipient
p = 0.774
Prothrombin 20210A mutation (Nº) (heterozygous) in recipient
p = 0.305
C677T MTHFR mutation (Nº) (wild type/heterozygous/homozygous) in recipient
p = 0.865
Clinical features of JAK2 V617F positive liver transplant recipients
JAK2 V617F Allele burden (%)
Alcohol cirrhosis and HCV cirrhosis
5.50 x 109
250 x 109
5.4 x 109
213 x 109
7.1 x 109
234 x 109
Budd-Chiari syndrome and PV
282 x 109
Pre-transplant PVT in liver recipients and clinical thrombophilia risk factors
Clinical thrombophilic risk factors in association with pre-transplant PVT cases
With pre-transplant PVT (n = 62)
Without pre-transplant PVT (n = 318)
p = 0.011
p = 0.451
Associated tumor (Yes/No)
p = 0.951
Diabetes mellitus and/or high lipid (Yes/No)
p = 0.043
Inflammatory disease (Yes/No)
p = N
p = 0.169
p = 0.531
Surgery Intervention (Yes/No)
p = 0.919
p = 0.004
Nephrotic syndrome (Yes/No)
p = 0.069
Myeloproliferative syndrome (Yes/No)
p = 0.003
p = 0.631
Cause of liver transplantation
p = 0.135
Infrequent (deficit alpha1 antitrypsin)
BHV and CHV
BHV and CHV and Tumor
Logistic Regression analysis of factors associated with pre-transplant PVT
Hazard Ratio (CI)
AGE (CONTINUOUS VARIABLE)
ASSOCIATED TUMOR (YES/NO)
DIABETES MELLITUS AND/OR HIGH LIPID (YES/NO)
CAUSE OF LIVER TRANSPLANTATION
FACTOR V LEIDEN
PROTHROMBIN 20210A MUTATION
MTHFR C677T MUTATION
During a liver transplantation, pre-transplant PVT, encountered in approximately 15% of candidates, increases surgical difficulties and post-operative PV re-thromboses . However, there is no extensive thrombophilia study in a large cohort of liver recipients. In our study, all cases are characterized by the presence of local thrombophilia risk factors: cirrhosis and other factors such as primary cancer, vascular abnormalities. We found obesity as the only clinical factor associated with pre-transplant PVT. Previously obesity has been considered to be a risk factor for the venous thromboembolism as well as arterial thrombosis [9–15], and was also previously reported as an independent risk factor for clinical decompensation in patients with cirrhosis  but it had not been previously associated with PVT. Plausible mechanisms to explain the relation between obesity and venous thrombosis include the existence of a proinflammatory, prothrombotic, and hypofibrinolitic milieu in the obese patients [12, 13].
The importance of genetic thrombophilia risk factors in PVT has been investigated in several studies [17–20] but all of them have excluded cases with local risk factors. The incidence of Factor V Leiden, prothrombin mutation, decreased PC, decreased PS, and decreased AT has been recorded between 3-30%, 3-22%, 0-26%, 2-43%, and 1-26%, respectively. In our study the incidence of Factor V Leiden and prothrombin mutation, was 2.4% and 4.5%, respectively. The incidence of Factor V Leiden and prothrombin mutations coincide with that seen in the general population and this fact could prove that genetic thrombophilia has no role in pre-transplant PVT in patients with cirrhosis.
JAK2 V617F testing represented an important advance in the diagnostic workup for the recognition of atypical myeloproliferative disease in BCS and PVT patients . Our results do not support the routine screening of JAK2 V617F mutation in patients with splanchnic thrombosis in terminal cirrhosis or malignancy, except when patients have Budd-Chiari syndrome. Our results do not contradict Plessier et al where patients with cirrhosis or malignacy were specifically excluded . Unlike previous studies [3, 23, 24],the presence of pre-transplant PVT did not influence the overall survival of recipients. Other authors also reported no significant differences between both groups for 1- to 10-year patient survival [25–28].
To the best of our knowledge, this is the first extensive genetic thrombophilia study in a large cohort of liver recipients. Obesity and diabetes mellitus and/or hyperlipidaemia were associated with pre-transplant PVT, but obesity was the only independent risk factor for pre-transplant PVT. We stress the importance of controlling the cardiovascular factors in patients with liver cirrhosis.
We thank Ian Ure for the English review and Sharon Forsyth of Biomedical Editing International for the Editing review; as well the liver transplantation team for the clinic data facility and Jose M. Murallas, Alicia Muñoz, Inmaculada Vidal, Ester Clemente and Pilar Lopez for the patient samples obtained and Dr A. Fuertes for the donor samples stored. We appreciate the advice of Dra T. Toledo and Dra. MA. Martin and the excellent technical assistance of Ana I. Corredor and Paloma Garcia-Tapias.
This work was supported by a grant from Foundation Mutua Madrileña del Automovil (grant 2004/009 and 2008/139).
- Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, Sauvanet A, Valla D, Durand F: Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005, 54 (5): 691-697. 10.1136/gut.2004.042796.View ArticlePubMedPubMed CentralGoogle Scholar
- Harmanci O, Bayraktar Y: Portal hypertension due to portal venous thrombosis: etiology, clinical outcomes. World J Gastroenterol. 2007, 13 (18): 2535-2540.View ArticlePubMedPubMed CentralGoogle Scholar
- Stieber AC, Zetti G, Todo S, Tzakis AG, Fung JJ, Marino I, Casavilla A, Selby RR, Starzl TE: The spectrum of portal vein thrombosis in liver transplantation. Ann Surg. 1991, 213 (3): 199-206. 10.1097/00000658-199103000-00003.View ArticlePubMedPubMed CentralGoogle Scholar
- Shaked A, Busuttil RW: Liver transplantation in patients with portal vein thrombosis and central portacaval shunts. Ann Surg. 1991, 214 (6): 696-702. 10.1097/00000658-199112000-00009.View ArticlePubMedPubMed CentralGoogle Scholar
- Lendoire J, Raffin G, Cejas N, Duek F, Barros Schelotto P, Trigo P, Quarin C, Garay V, Imventarza O: Liver transplantation in adult patients with portal vein thrombosis: risk factors, management and outcome. HPB (Oxford). 2007, 9 (5): 352-356. 10.1080/13651820701599033.View ArticleGoogle Scholar
- Ayala R, Martinez-Lopez J, Cedena T, Bustelos R, Jimenez C, Moreno E, Ribera C: Recipient and donor thrombophilia and the risk of portal venous thrombosis and hepatic artery thrombosis in liver recipients. BMC Gastroenterol. 2011, 11 (1): 130-10.1186/1471-230X-11-130.View ArticlePubMedPubMed CentralGoogle Scholar
- Rapado I, Grande S, Albizua E, Ayala R, Hernandez JA, Gallardo M, Gilsanz F, Martinez-Lopez J: High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms. J Mol Diagn. 2009, 11 (2): 155-161. 10.2353/jmoldx.2009.080110.View ArticlePubMedPubMed CentralGoogle Scholar
- Feng S, Humar A, Pomfret E, Fishbein T, Gaber O: Surgical challenges in transplantation: the Fourth Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium. Am J Transplant. 2005, 5 (3): 428-435. 10.1111/j.1600-6143.2004.00718.x.View ArticlePubMedGoogle Scholar
- Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997, 277 (8): 642-645. 10.1001/jama.1997.03540320044033.View ArticlePubMedGoogle Scholar
- Stein PD, Beemath A, Olson RE: Obesity as a risk factor in venous thromboembolism. Am J Med. 2005, 118 (9): 978-980. 10.1016/j.amjmed.2005.03.012.View ArticlePubMedGoogle Scholar
- Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW: Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008, 117 (1): 93-102. 10.1161/CIRCULATIONAHA.107.709204.View ArticlePubMedGoogle Scholar
- Allman-Farinelli MA: Obesity and venous thrombosis: a review. Semin Thromb Hemost. 2011, 37 (8): 903-907. 10.1055/s-0031-1297369.View ArticlePubMedGoogle Scholar
- van Langevelde K, Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Cannegieter SC: Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as two sides of the spectrum. Blood. 2012, 120 (5): 933-946. 10.1182/blood-2012-02-407551.View ArticlePubMedGoogle Scholar
- Lamattina JC, Foley DP, Fernandez LA, Pirsch JD, Musat AI, D'Alessandro AM, Mezrich JD: Complications associated with liver transplantation in the obese recipient. Clin Transplant. 2012, 10.1111/j.1399-0012.2012.01669.x. first published on Jun 13Google Scholar
- Pearson V, Ruzas C, Krebs NF, Goldenberg NA, Manco-Johnson MJ, Bernard TJ: Overweight and Obesity Are Increased in Childhood-Onset Cerebrovascular Disease. J Child Neurol. 2012, 10.1177/0883073812446160. first published on May 30, 2012Google Scholar
- Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, et al: Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011, 54 (2): 555-561. 10.1002/hep.24418.View ArticlePubMedPubMed CentralGoogle Scholar
- Egesel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y: The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol. 2000, 30 (1): 66-71. 10.1097/00004836-200001000-00013.View ArticlePubMedGoogle Scholar
- Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, et al: Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case–control study. Blood. 2000, 96 (7): 2364-2368.PubMedGoogle Scholar
- Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Dell'era A, Pappalardo E, Mannucci PM: Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology. 2005, 41 (3): 603-608. 10.1002/hep.20591.View ArticlePubMedGoogle Scholar
- Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D: Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000, 31 (3): 587-591. 10.1002/hep.510310307.View ArticlePubMedGoogle Scholar
- Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, et al: The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008, 111 (10): 4922-4929. 10.1182/blood-2007-11-125328.View ArticlePubMedGoogle Scholar
- Plessier A, Darwish-Murad S, Hernandez-Guerra M, Consigny Y, Fabris F, Trebicka J, Heller J, Morard I, Lasser L, Langlet P, et al: Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology. 2010, 51 (1): 210-218. 10.1002/hep.23259.View ArticlePubMedGoogle Scholar
- Englesbe MJ, Kubus J, Muhammad W, Sonnenday CJ, Welling T, Punch JD, Lynch RJ, Marrero JA, Pelletier SJ: Portal vein thrombosis and survival in patients with cirrhosis. Liver Transpl. 2010, 16 (1): 83-90. 10.1002/lt.21941.View ArticlePubMedGoogle Scholar
- Davidson BR, Gibson M, Dick R, Burroughs A, Rolles K: Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. Transplantation. 1994, 57 (8): 1174-1177. 10.1097/00007890-199404270-00006.View ArticlePubMedGoogle Scholar
- Molmenti EP, Roodhouse TW, Molmenti H, Jaiswal K, Jung G, Marubashi S, Sanchez EQ, Gogel B, Levy MF, Goldstein RM, et al: Thrombendvenectomy for organized portal vein thrombosis at the time of liver transplantation. Ann Surg. 2002, 235 (2): 292-296. 10.1097/00000658-200202000-00019.View ArticlePubMedPubMed CentralGoogle Scholar
- Manzanet G, Sanjuan F, Orbis P, Lopez R, Moya A, Juan M, Vila J, Asensi J, Sendra P, Ruiz J, et al: Liver transplantation in patients with portal vein thrombosis. Liver Transpl. 2001, 7 (2): 125-131. 10.1053/jlts.2001.21295.View ArticlePubMedGoogle Scholar
- Dumortier J, Czyglik O, Poncet G, Blanchet MC, Boucaud C, Henry L, Boillot O: Eversion thrombectomy for portal vein thrombosis during liver transplantation. Am J Transplant. 2002, 2 (10): 934-938. 10.1034/j.1600-6143.2002.21009.x.View ArticlePubMedGoogle Scholar
- Gimeno FA, Calvo J, Loinaz C, Meneu JC, Perez B, Gomez R, Jimenez C, Abradelo M, Moreno A, Sesma A, et al: Comparative analysis of the results of orthotopic liver transplantation in patients with and without portal vein thrombosis. Transplant Proc. 2005, 37 (9): 3899-3903. 10.1016/j.transproceed.2005.10.085.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/12/114/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.